Loading the company…
Loading the company…
In 2025, Beta Bionics reported engagement with 3,861 surgeons and other clinicians in the states MedaRep covers, worth $286K in consulting, speaking, meals and travel for its device products, the most in Texas ($36K to 474). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($36K, 474 engaged), Florida ($26K, 329 engaged), New York ($22K, 204 engaged), California ($20K, 257 engaged), Ohio ($14K, 162 engaged).
In the last ten years FDA made 5 decisions for Beta Bionics (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (2). The latest was on 2026-09-11.
| Family | Decisions on record |
|---|---|
| CGM & insulin pump management | 5 |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Beta Bionics.